Plain-English answer
The largest U.S. reimbursement pitfall for foreign healthcare companies is confusing permission to sell with payment for use. FDA authorization, a billing code, a published study, and physician interest are each useful, but none alone guarantees coverage or payment.
Core strategic decision
The company must decide whether the first U.S. revenue path is payer reimbursement, hospital budget, employer payment, cash pay, distributor pull-through, or partner-funded adoption. This decision should determine the regulatory pathway, reimbursement workplan, channel model, staffing level, evidence investment, and first customer segment.
Evidence and diligence questions
The payer story should prove who should receive the product, why it is medically necessary, what alternative it replaces, and what cost or outcome benefit justifies coverage. Evidence should be prepared for the relevant decision-maker rather than repurposed mechanically from China-facing development, marketing, or regulatory materials.
U.S. entry readiness checklist
| Question | Why it matters | Failure mode |
|---|---|---|
| What is the U.S. route to permission? | FDA pathway, establishment obligations, labeling, quality systems, and postmarket requirements define legal access. | Choosing the wrong claim or pathway and then rebuilding the dossier. |
| What is the route to payment? | Codes, coverage, payment, site of care, medical necessity, and payer policy define economic access. | Receiving authorization but lacking a reimbursable use case. |
| What is the route to trust? | Evidence, U.S. references, support, privacy, liability controls, and local accountability reduce adoption friction. | Assuming low price or China scale overcomes credibility barriers. |
Commercialization implications
A China-origin healthcare company should not treat the United States as simply a higher-priced market. It is a fragmented market where the buyer, payer, user, regulator, and risk-holder are often different organizations.
How to read the opportunity
Define the U.S. entry objective
Clarify whether the company seeks FDA authorization, reimbursement, strategic partnering, investor validation, distributor coverage, or full commercialization.
Map the U.S. decision chain
Identify the regulator, code owner, payer, hospital committee, physician champion, distributor, patient, privacy officer, and risk manager who can block adoption.
Localize proof and support
Convert China evidence, product design, documentation, service, privacy architecture, and commercial claims into U.S.-credible operating assets.